Fnu Safarudin1,2, Chibuzo O Iloabuchi1, Amit Ladani3, Usha Sambamoorthi1. 1. Department of Pharmaceutical Systems and Policy, West Virginia University School of Pharmacy, USA. 2. School of Mathematics and Natural Sciences, Tadulako University, Indonesia. 3. Department of Medicine, Section of Rheumatology, West Virginia University School of Pharmacy, USA.
Abstract
BACKGROUND: Some studies have shown that beta-blocker use is associated with better cognitive impairment. However, these studies did not control for pain. The relationship between pain and cognitive impairment has been exhaustively investigated. The association of beta blockers to cognitive impairment in the presence of chronic pain is still unknown. OBJECTIVE: To examine the independent association of beta-blocker use to cognitive impairment among adults with hypertension or Cardiovascular Diseases (CVDs). METHODS: We used a cross-sectional study design. We derived data on 8,279 adults from the 2015 Medical Expenditure Panel Survey (MEPS). Study participants were adults (age > 21 years), with hypertension or CVDs and without intracranial injury, Parkinson, Alzheimer's disease and Related Dementia. Cognitive impairment was measured based on 1) confusion or memory loss; 2) problems making decisions, or 3) supervision for participant's safety. Anti-hypertensive medications were categorized into 1) beta-blockers; 2) other anti-hypertensives; and 3) no antihypertensive medication. We used multivariable survey logistic regressions to examine the association between beta-blockers and cognitive impairment after controlling for biological factors, pain, chronic conditions, socioeconomic status, access to healthcare services, behavioral, socio-cultural and external environmental factors. RESULTS: Overall, 24.2%, 41.9%, and 33.9% reported using beta-blockers, other antihypertensives, and no antihypertensive medications, respectively; 18.1% participants reported cognitive impairment. After controlling for pain, beta-blocker use was not significantly associated with cognitive impairment (AOR= 1.22, 95%CI= 1.00-1.49). In fully adjusted models, the AOR for beta-blockers use was 1.05 (95%CI = 0.84-1.31). CONCLUSION: In this first large cross-sectional study, we found that the use of beta-blockers was not associated with cognitive impairment. Future prospective studies that include pain management and blood pressure control are needed to confirm the findings.
BACKGROUND: Some studies have shown that beta-blocker use is associated with better cognitive impairment. However, these studies did not control for pain. The relationship between pain and cognitive impairment has been exhaustively investigated. The association of beta blockers to cognitive impairment in the presence of chronic pain is still unknown. OBJECTIVE: To examine the independent association of beta-blocker use to cognitive impairment among adults with hypertension or Cardiovascular Diseases (CVDs). METHODS: We used a cross-sectional study design. We derived data on 8,279 adults from the 2015 Medical Expenditure Panel Survey (MEPS). Study participants were adults (age > 21 years), with hypertension or CVDs and without intracranial injury, Parkinson, Alzheimer's disease and Related Dementia. Cognitive impairment was measured based on 1) confusion or memory loss; 2) problems making decisions, or 3) supervision for participant's safety. Anti-hypertensive medications were categorized into 1) beta-blockers; 2) other anti-hypertensives; and 3) no antihypertensive medication. We used multivariable survey logistic regressions to examine the association between beta-blockers and cognitive impairment after controlling for biological factors, pain, chronic conditions, socioeconomic status, access to healthcare services, behavioral, socio-cultural and external environmental factors. RESULTS: Overall, 24.2%, 41.9%, and 33.9% reported using beta-blockers, other antihypertensives, and no antihypertensive medications, respectively; 18.1% participants reported cognitive impairment. After controlling for pain, beta-blocker use was not significantly associated with cognitive impairment (AOR= 1.22, 95%CI= 1.00-1.49). In fully adjusted models, the AOR for beta-blockers use was 1.05 (95%CI = 0.84-1.31). CONCLUSION: In this first large cross-sectional study, we found that the use of beta-blockers was not associated with cognitive impairment. Future prospective studies that include pain management and blood pressure control are needed to confirm the findings.
Authors: Arthur F Kramer; Louis Bherer; Stanley J Colcombe; Willie Dong; William T Greenough Journal: J Gerontol A Biol Sci Med Sci Date: 2004-09 Impact factor: 6.053
Authors: Katherine T Mills; Katherine M Obst; Wei Shen; Sandra Molina; Hui-Jie Zhang; Hua He; Lisa A Cooper; Jiang He Journal: Ann Intern Med Date: 2017-12-26 Impact factor: 25.391
Authors: Vahid Eslami; Mindy J Katz; Robert S White; Erin Sundermann; Julie M Jiang; Ali Ezzati; Richard B Lipton Journal: Gerontology Date: 2016-08-04 Impact factor: 5.140
Authors: Thanh G N Ton; Thomas DeLeire; Suepattra G May; Ningqi Hou; Mahlet G Tebeka; Er Chen; Joshua Chodosh Journal: Alzheimers Dement Date: 2016-09-28 Impact factor: 21.566
Authors: Frank Jessen; Steffen Wolfsgruber; Birgitt Wiese; Horst Bickel; Edelgard Mösch; Hanna Kaduszkiewicz; Michael Pentzek; Steffi G Riedel-Heller; Tobias Luck; Angela Fuchs; Siegfried Weyerer; Jochen Werle; Hendrik van den Bussche; Martin Scherer; Wolfgang Maier; Michael Wagner Journal: Alzheimers Dement Date: 2013-01-30 Impact factor: 21.566
Authors: Rebecca P Gelber; G Webster Ross; Helen Petrovitch; Kamal H Masaki; Lenore J Launer; Lon R White Journal: Neurology Date: 2013-08-02 Impact factor: 9.910
Authors: Lusi Zhang; Scot Kristian Hill; Bin Guo; Baolin Wu; Ney Alliey-Rodriguez; Seenae Eum; Paulo Lizano; Elena I Ivleva; James L Reilly; Richard S E Keefe; Sarah K Keedy; Carol A Tamminga; Godfrey D Pearlson; Brett A Clementz; Matcheri S Keshavan; Elliot S Gershon; John A Sweeney; Jeffrey R Bishop Journal: Prog Neuropsychopharmacol Biol Psychiatry Date: 2021-10-29 Impact factor: 5.067